本文選題：胰腺癌 + 免疫治療��； 參考：《中國人民解放軍醫(yī)學(xué)院》2016年博士論文

【摘要】：研究背景：胰腺癌惡性程度高,預(yù)后極差,包括手術(shù)、化療和放療在內(nèi)的腫瘤傳統(tǒng)治療手段在殺傷腫瘤的同時(shí)會(huì)激發(fā)機(jī)體炎癥反應(yīng),并對(duì)抗腫瘤免疫造成一定程度的抑制和損傷。流行學(xué)和分子生物學(xué)證據(jù)顯示胰腺癌的發(fā)生和發(fā)展與慢性炎癥密切相關(guān)。NLRP3炎性體是一種由NLRP3蛋白、銜接蛋白ASC和Caspase-1前體構(gòu)成的蛋白復(fù)合物,是調(diào)節(jié)炎癥反應(yīng)的重要平臺(tái),在機(jī)體受到刺激的情況下,NLRP3蛋白能夠募集銜接蛋白ASC和Caspase-1前體,形成炎性體復(fù)合物,介導(dǎo)IL-1β和IL-18的成熟分泌,進(jìn)而調(diào)控炎癥反應(yīng)。研究證實(shí)IL-18可增強(qiáng)胰腺癌細(xì)胞侵襲能力.而IL-18升高則與胰腺癌預(yù)后不佳相關(guān)。由此推斷,NLRP3炎性體失調(diào)可能與胰腺癌的發(fā)生和發(fā)展相關(guān),但目前尚無相關(guān)研究。免疫治療已經(jīng)成為腫瘤治療的第四大手段,CIK細(xì)胞作為免疫治療的重要部分,已經(jīng)在臨床治療中得到應(yīng)用,但其在殺傷腫瘤細(xì)胞的同時(shí)可以引起細(xì)胞因子大量釋放,誘發(fā)細(xì)胞因子釋放綜合征。此外,免疫細(xì)胞的抗腫瘤免疫能力還受到NLRP3炎性體的抑制。因此,抑制NLRP3炎性體聯(lián)合免疫細(xì)胞治療,在抑制腫瘤相關(guān)炎性反應(yīng)的同時(shí)重建并增強(qiáng)抗腫瘤免疫,可以實(shí)現(xiàn)協(xié)同抗腫瘤效果最大化。目的：研究NLRP3炎性體在胰腺癌中的表達(dá)情況及意義,建立免疫細(xì)胞的制備和檢測(cè)技術(shù)平臺(tái),探討NLRP3炎性體調(diào)控聯(lián)合CIK細(xì)胞治療胰腺癌的可行性和有效性。方法：1)利用免疫組化檢測(cè)組織芯片中98例胰腺癌組織中NLRP3炎性體的表達(dá),分析NLRP3炎性體各組分表達(dá)與胰腺癌患者臨床病理因素的相關(guān)性,進(jìn)行生存分析研究NLRP3炎性體與胰腺癌預(yù)后的相關(guān)性。2)建立CIK制備和檢測(cè)技術(shù)平臺(tái),取健康志愿者外周血,分離PBMC,培養(yǎng)擴(kuò)增為CIK細(xì)胞，流式細(xì)胞術(shù)檢測(cè)PBMC和C1K細(xì)胞中活化T細(xì)胞和中央型記憶T細(xì)胞比例,并進(jìn)行比較以評(píng)估CIK細(xì)胞的活化程度和抗腫瘤能力。3)采用Western Blot檢測(cè)人胰腺癌細(xì)胞株SW1990和PANC-1中NLRP3炎性體的表達(dá),并檢測(cè)MNS對(duì)胰腺癌細(xì)胞株中NLRP3炎性體表達(dá)的影響。使用劃痕試驗(yàn)、Transwell侵襲和遷移試驗(yàn)以及CCK-8法評(píng)估抑制NLRP3炎性體對(duì)胰腺癌細(xì)胞侵襲轉(zhuǎn)移及增殖能力的影響。4)利用裸鼠左側(cè)腋下皮內(nèi)注射人胰腺癌細(xì)胞株SW1990,建立BLAB/c裸鼠胰腺癌皮下瘤模型，，將24只荷瘤裸鼠以每組6只的數(shù)量隨機(jī)分為MNS(腹腔注射)組、CIK(尾靜脈注射)組、MNS(腹腔注射)聯(lián)合CIK(尾靜脈注射)組以及對(duì)照組(溶媒)，以腫瘤體積、瘤重以及抑瘤率為指標(biāo)觀察各干預(yù)組對(duì)胰腺癌皮下瘤生長的影響。治療2周后處死裸鼠,取皮下瘤進(jìn)行HE和免疫組化檢測(cè)，進(jìn)一步分析抑制炎性體聯(lián)合CIK細(xì)胞對(duì)胰腺癌的治療效應(yīng)及內(nèi)在機(jī)制。結(jié)果：1)免疫組化結(jié)果顯示NLRP3炎性體各組分在胰腺癌組織中表達(dá)水平較癌旁組織明顯升高,且與胰腺癌臨床分期以及淋巴結(jié)侵犯相關(guān)(P0.05),此外NLRP3炎性體各組分異常表達(dá)均與胰腺癌預(yù)后相關(guān),其中高表達(dá)NLRP3的患者的中位生存時(shí)間(12個(gè)月)明顯短于NLRP3低表達(dá)者(21個(gè)月,P0.01),高表達(dá)ASC(13個(gè)月 VS 18個(gè)月,P0.01)、高表達(dá)Caspase-1(13個(gè)月VS 17個(gè)月，P0.01)以及高表達(dá)IL-1β(13個(gè)月 VS 18個(gè)月,P0.01)也均與胰腺癌預(yù)后不佳有關(guān)。2)流式細(xì)胞術(shù)顯示CIK細(xì)胞中CD3+CD8+T細(xì)胞和CD3+CD56+T細(xì)胞比例分別高達(dá)71.31%±18.77%和34.62%±15.67%。相比PBMC,培養(yǎng)成熟的CIK細(xì)胞中活化T細(xì)胞和中央型記憶T細(xì)胞比例顯著升高(P0.05)。3)Western Blot檢測(cè)顯示人胰腺癌細(xì)胞株P(guān)ANC-1和SW1990均表達(dá)NLRP3炎性體,此外MNS可以顯著抑制胰腺癌細(xì)胞株中NLRP3炎性體的表達(dá)(P0.05)：Transwe11試驗(yàn)和劃痕實(shí)驗(yàn)結(jié)果顯示抑制NLRP3炎性體組分后,胰腺癌細(xì)胞侵襲和遷移能力顯著降低(P0.05);CCK8實(shí)驗(yàn)結(jié)果顯示抑制NLRP3炎性體能夠抑制胰腺癌細(xì)胞株的增殖,對(duì)CIK細(xì)胞增殖則無明顯影響。4)成功構(gòu)建裸鼠胰腺癌皮下瘤模型,致瘤率100%,體內(nèi)實(shí)驗(yàn)顯示MNS腹腔注射聯(lián)合CIK細(xì)胞尾靜脈注射抗腫瘤效果最強(qiáng),與對(duì)照組、CIK組和MNS組相比差異具有統(tǒng)計(jì)學(xué)意義(P0.05)。皮下瘤HE和免疫組化檢測(cè)顯示聯(lián)合治療組腫瘤呈現(xiàn)為片狀壞死,且NLRP3炎性體表達(dá)明顯下調(diào)。結(jié)論：1)胰腺癌組織和細(xì)胞株中高表達(dá)NLRP3炎性體。2)抑制NLRP3炎性體可以抑制胰腺癌的增殖和轉(zhuǎn)移,但對(duì)免疫細(xì)胞無顯著影響。3)抑制NLRP3炎性體聯(lián)合CIK細(xì)胞治療在在抑制腫瘤相關(guān)炎性反應(yīng)的同時(shí)重建并增強(qiáng)抗腫瘤免疫,實(shí)現(xiàn)更強(qiáng)的聯(lián)合抗腫瘤效果。
[Abstract]:Background: pancreatic cancer has a high malignancy and a poor prognosis. Traditional treatments, including surgery, chemotherapy and radiotherapy, can stimulate the body's inflammatory response while killing the tumor, and cause a certain degree of inhibition and damage against tumor immunity. Epidemiology and molecular biological evidence show the occurrence and development and chronic of pancreatic cancer. Inflammation closely related.NLRP3 is a protein complex composed of NLRP3 protein, ASC and Caspase-1 precursor. It is an important platform for regulating inflammatory response. In the case of stimulation of the body, NLRP3 protein can collect ASC and Caspase-1 precursors, form inflammatory complex, mediate the maturity of IL-1 beta and IL-18. IL-18 can enhance the invasiveness of pancreatic cancer cells. The increase of IL-18 is associated with poor prognosis of pancreatic cancer. It is concluded that the dysregulation of NLRP3 may be associated with the occurrence and development of pancreatic cancer, but there is no related research. Immunotherapy has become the fourth major means of cancer treatment, CIK thin. As an important part of immunotherapy, cell has been used in clinical treatment, but it can cause cytokine release and induce cytokine release syndrome at the same time of killing tumor cells. In addition, the anti-tumor immunity ability of immune cells is also inhibited by NLRP3 inflammatory body. Therefore, inhibition of NLRP3 inflammatory body combined with immunization. Cell therapy, while reconstructing and enhancing anti-tumor immunity, can maximize the synergistic anti-tumor effect. Objective: To study the expression and significance of NLRP3 inflammatory body in pancreatic cancer, to establish an immune cell preparation and detection technology platform, and to explore the regulation of NLRP3 inflammatory body combined with CIK cells for the treatment of the pancreas The feasibility and effectiveness of cancer. Methods: 1) the expression of NLRP3 inflammatory body in 98 cases of pancreatic cancer tissues was detected by immunohistochemistry. The correlation between the expression of NLRP3 inflammatory components and the clinicopathological factors of pancreatic cancer patients was analyzed, and the survival analysis was carried out to study the correlation between the NLRP3 inflammatory body and the prognosis of pancreatic cancer. The CIK preparation and the establishment of CIK were established. The testing technology platform was used to take the peripheral blood of healthy volunteers, isolate PBMC and develop CIK cells. Flow cytometry was used to detect the proportion of activated T cells and central memory T cells in PBMC and C1K cells, and to compare the activation degree of CIK cells and the ability to resist tumor.3). Western Blot was used to detect the SW1990 and PANC-1 of human pancreatic cancer cell lines. The expression of NLRP3 inflammatory body and the effect of MNS on the expression of NLRP3 inflammatory body in pancreatic cancer cell lines. Using scratch test, Transwell invasion and migration test, and CCK-8 method to evaluate the effect of NLRP3 on the invasion, metastasis and proliferation of pancreatic cancer cells,.4) by injecting human pancreatic cancer cell line SW1 in the left subaxillary skin of nude mice,.4. 990, a model of subcutaneous tumor of BLAB/c nude mice was established, and 24 tumor bearing nude mice were randomly divided into MNS (intraperitoneal injection) group, CIK (tail vein injection) group, MNS (intraperitoneal injection) combined with CIK (caudal vein injection) group and control group (dissolvent). The tumor volume, tumor weight and tumor suppressor rate were used to observe the subcutaneous of pancreatic cancer in the intervention groups. The effect of tumor growth. After 2 weeks of treatment, the nude mice were killed and the subcutaneous tumor was examined by HE and immunohistochemistry. The therapeutic effect and internal mechanism of the inhibition of inflammatory body combined with CIK cells to pancreatic cancer were further analyzed. Results: 1) the immunohistochemical results showed that the expression level of NLRP3 inflammatory components in the pancreatic cancer group was significantly higher than that in the paracancerous tissue. The clinical staging of pancreatic cancer and lymph node invasion (P0.05) were associated with the prognosis of pancreatic cancer. The median survival time (12 months) of the patients with high expression of NLRP3 (21 months, P0.01), high expression of ASC (13 months VS, 18 months, P0.01), and high expression of Caspase-1 (13) were all associated with the prognosis of pancreatic cancer. VS 17 months, P0.01) and high expression of IL-1 beta (13 months VS and 18 months, P0.01) were also associated with poor prognosis of pancreatic cancer.2) flow cytometry showed that the proportion of CD3+CD8+T cells and CD3+CD56+T cells in CIK cells was up to 71.31% + 18.77% and 34.62% + 15.67%. compared to PBMC. A significant increase in cell proportion (P0.05).3) Western Blot detection showed that human pancreatic cancer cell lines, PANC-1 and SW1990, expressed NLRP3 inflammatory bodies. In addition, MNS could significantly inhibit the expression of NLRP3 inflammatory bodies in pancreatic cancer cell lines (P0.05):Transwe11 test and scratch test results showed invasion and migration of pancreatic cancer cells after inhibition of the NLRP3 inflammatory components. The results showed a significant decrease in ability (P0.05); the results of CCK8 test showed that inhibition of NLRP3 inflammation could inhibit the proliferation of pancreatic cancer cell lines, and had no obvious influence on the proliferation of CIK cells. The model of subcutaneous tumor of pancreatic cancer in nude mice was successfully constructed, the tumor rate was 100%. In vivo experiments showed that MNS intraperitoneal injection of CIK cells combined with CIK cells had the strongest anti tumor effect, and compared with the control. The difference between group CIK and group MNS was statistically significant (P0.05). Subcutaneous tumor HE and immunohistochemistry showed that the tumor in the combined treatment group was flaky necrosis and the expression of NLRP3 inflammatory body was obviously down-regulated. Conclusion: 1) the high expression of NLRP3 inflammatory.2 in pancreatic cancer tissues and cell lines can inhibit the proliferation of pancreatic cancer and inhibit the proliferation of pancreatic cancer. Metastasis, but there is no significant effect on immune cells,.3) inhibition of NLRP3 inflammatory body combined with CIK cell therapy in the suppression of tumor related inflammatory responses while reconstructing and enhancing anti-tumor immunity to achieve a stronger combined antitumor effect.
【學(xué)位授予單位】：中國人民解放軍醫(yī)學(xué)院
【學(xué)位級(jí)別】：博士
【學(xué)位授予年份】：2016
【分類號(hào)】：R735.9

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 王振磊;孫萍萍;李天曉;黎曙霞;;白頭翁湯激活NLRP3炎癥小體治療炎癥性腸病的研究[J];中藥材;2012年08期

2 鈕憶欣;蘇青;;NLRP3的炎性反應(yīng)在2型糖尿病中的作用[J];醫(yī)學(xué)綜述;2011年02期

3 宋智;姜瀾;林正梅;;NLRP3及其在口腔疾病中的研究進(jìn)展[J];中華口腔醫(yī)學(xué)研究雜志(電子版);2012年05期

4 毛開睿;孫兵;;NLRP3炎癥小體研究進(jìn)展[J];現(xiàn)代免疫學(xué);2011年01期

5 王定坤;陳廣;陸付耳;;NLRP3炎癥小體與2型糖尿病的研究進(jìn)展[J];生理科學(xué)進(jìn)展;2014年02期

6 隋永恒;連敏;華靜;;體內(nèi)外高脂對(duì)肝臟NLRP3炎性小體相關(guān)基因表達(dá)的影響[J];胃腸病學(xué);2014年01期

7 張懿;劉磊;劉韻資;張婷;蔣春雷;;NLRP3炎性小體研究新進(jìn)展[J];現(xiàn)代生物醫(yī)學(xué)進(jìn)展;2014年09期

8 蔣建燁;田nI;張艷;;NLRP3炎癥體與炎癥性疾病[J];微生物學(xué)免疫學(xué)進(jìn)展;2012年01期

9 宋麗敏;尚游;吳艷;;NLRP3炎性小體在中樞神經(jīng)系統(tǒng)炎癥中的作用[J];中風(fēng)與神經(jīng)疾病雜志;2014年04期

10 ;生化與細(xì)胞所研究發(fā)現(xiàn)TRIM30負(fù)性調(diào)控NLRP3炎癥小體的激活[J];東北農(nóng)業(yè)大學(xué)學(xué)報(bào);2010年11期

相關(guān)會(huì)議論文 前4條

1 鐘琳曄;楊汀;;NLRP3炎癥小體及其激活產(chǎn)物在慢性阻塞性肺疾病中的作用研究進(jìn)展[A];中華醫(yī)學(xué)會(huì)呼吸病學(xué)年會(huì)——2013第十四次全國呼吸病學(xué)學(xué)術(shù)會(huì)議論文匯編[C];2013年

2 王振磊;孫萍萍;李天曉;黎曙霞;;白頭翁湯激活NLRP3炎癥小體治療炎癥性腸病的研究[A];2013年廣東省藥師周大會(huì)論文集[C];2013年

3 黃馨;軒東英;章錦才;;NLRP3信號(hào)通路在牙周炎與糖尿病相互關(guān)系中的研究[A];第十次全國牙周病學(xué)學(xué)術(shù)會(huì)議論文摘要匯編[C];2014年

4 王彥君;龔國清;陳建軍;陳刪;牛永芝;熊利燕;孔維佳;;慢性鼻竇炎伴與不伴鼻息肉與NLRP3炎癥小體的關(guān)系[A];中華醫(yī)學(xué)會(huì)第十三次全國耳鼻咽喉——頭頸外科學(xué)術(shù)會(huì)議論文匯編[C];2013年

相關(guān)博士學(xué)位論文 前9條

1 王玢tx;新城疫病毒激活NLRP3炎癥小體及其作用[D];中國農(nóng)業(yè)科學(xué)院;2016年

2 孔祥;NLRP3炎癥小體在糖化終末產(chǎn)物誘導(dǎo)的胰島β細(xì)胞損傷中的作用研究[D];上海交通大學(xué);2015年

3 肖孟景;NLRP3炎性體在深二度燒傷創(chuàng)面早期加深中的作用及自噬對(duì)其的調(diào)控[D];中國人民解放軍醫(yī)學(xué)院;2016年

4 潘楊;NLRP3炎癥小體在帕金森病神經(jīng)炎癥中的作用及治療學(xué)意義研究[D];南京醫(yī)科大學(xué);2016年

5 張懿;NLRP3炎性小體在抑郁樣行為中的作用及分子機(jī)制[D];第二軍醫(yī)大學(xué);2016年

6 劉海亮;抑制NLRP3炎性體聯(lián)合CIK細(xì)胞治療胰腺癌的實(shí)驗(yàn)研究[D];中國人民解放軍醫(yī)學(xué)院;2016年

7 吳劍波;NLRP3炎性體對(duì)機(jī)械通氣所致肺損傷的調(diào)節(jié)作用[D];山東大學(xué);2014年

8 付岳;白藜蘆醇抑制輻射誘導(dǎo)的NLRP3炎癥蛋白復(fù)合體激活的機(jī)理研究[D];北京協(xié)和醫(yī)學(xué)院;2014年

9 鄭飛;動(dòng)脈粥樣硬化中NLRP3炎癥體的組織學(xué)表達(dá)及基因干預(yù)研究[D];山東大學(xué);2014年

相關(guān)碩士學(xué)位論文 前10條

1 謝海龍;2型糖尿病患者外周血單個(gè)核細(xì)胞NLRP3炎性體mRNA表達(dá)和炎性因子水平與動(dòng)脈粥樣硬化相關(guān)性研究[D];長江大學(xué);2015年

2 沈文文;miR-20a對(duì)AA大鼠模型滑膜細(xì)胞中NLRP3炎癥小體的調(diào)控作用及其機(jī)制的研究[D];安徽醫(yī)科大學(xué);2015年

3 徐曉艷;TIM-4與2型糖尿病的相關(guān)性及對(duì)NLRP3炎性體的抑制效應(yīng)[D];山東大學(xué);2015年

4 許倡濤;TXNIP介導(dǎo)的心肌微血管內(nèi)皮細(xì)胞NLRP3炎性小體活化在心肌缺血再灌注損傷中的機(jī)制研究[D];第四軍醫(yī)大學(xué);2015年

5 魯理;1,25(OH)2D3通過抑制NLRP3炎癥小體激活保護(hù)高糖誘導(dǎo)的視網(wǎng)膜血管內(nèi)皮細(xì)胞功能障礙[D];蚌埠醫(yī)學(xué)院;2015年

6 周航;小檗堿通過抑制NLRP3炎癥小體活化改善小鼠胰島素抵抗[D];南京大學(xué);2014年

7 楊加偉;糖皮質(zhì)激素調(diào)控NLRP3炎性體表達(dá)在ALI/ARDS中的作用和機(jī)制[D];蘇州大學(xué);2016年

8 楊其彬;NLRP3炎性體信號(hào)通路在急性痛風(fēng)性關(guān)節(jié)炎患者中變化的研究[D];川北醫(yī)學(xué)院;2011年

9 劉園園;豬繁殖與呼吸綜合征病毒激活NLRP3炎癥小體的研究[D];西北農(nóng)林科技大學(xué);2014年

10 談俊;氟西汀對(duì)NLRP3炎癥小體激活的抑制作用及其機(jī)制研究[D];南京醫(yī)科大學(xué);2013年

本文編號(hào)：1930166